Keros Therapeutics (KROS) KER-050 'derisked and differentiated' following Geron imetelstat news - Truist Securities
Tweet Send to a Friend
Truist Securities analyst Srikripa Devarakonda reiterated a Buy rating and $100.00 price target on Keros Therapeutics (NASDAQ: KROS) as Geron's ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
